1-2 of 2
Stefan Duensing
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma

Open Access
Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates) , Karger e-Journal Backfile Collection 2023 , Further Areas
Marie Mikuteit, Stefanie Zschäbitz, Christine Stöhr, Edwin Herrmann, Iris Polifka, Abbas Agaimy, Lutz Trojan, Philipp Ströbel, Frank Becker, Christian Wülfing, Peter Barth, Michael Stöckle, Michael Staehler, Christian Stief, Axel Haferkamp, Markus Hohenfellner, Stefan Duensing, Stephan Macher-Göppinger, Bernd Wullich, Joachim Noldus, Walburgis Brenner, Frederik Roos, Bernhard Walter, Wolfgang Otto, Maximilian Burger, Maximillian Erlmeier, Andres Jan Schrader, Arndt Hartmann, Franziska Erlmeier, Sandra Steffens, German Network Of Kidney Cancer
Journal: Urologia Internationalis
Urol Int (2023) 107 (7): 713–722.
https://doi.org/10.1159/000529898
Published Online: 08 August 2023
View article titled, Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma
Open the PDF for Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma in another window
Journal Articles

Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period

Available to Purchase
Subject Area:
Further Areas
Eva Bonetti, Maximilian Jenzer, Cathleen Nientiedt, Adam Kaczorowski, Christine Geisler, Stefanie Zschäbitz, Dirk Jäger, Markus Hohenfellner, Stefan Duensing, Philipp Reimold
Journal: Urologia Internationalis
Urol Int (2022) 106 (11): 1158–1167.
https://doi.org/10.1159/000524097
Published Online: 27 April 2022
View article titled, Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period
Open the PDF for Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period in another window